M
MEDIWOUND
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutics based on its patented proteolytic enzyme technology that addresses unmet needs in the fields of severe burns, chronic, and other hard-to-heal wounds. MediWound was founded in 2001 and is based in Israel.
Country/Area ：Israel
Company Email ：contact@mediwound.com
Industry ：BiotechnologyGifts & CraftsElectronicsHealthcareSchool & Office SuppliesPharmaceuticals
Company address ：42 Hayarkon St, Yavne, Central District, 8122745, Israel
Company website ：*****
Company phone ：+972 779714100
Established ：2001
Company Revenue ：$20,934,000
Number of employees ：67
SIC Code ：28283
NAICS Code ：54541
Main Products ：MediWound Announces the Appointment of Hani Luxenburg as Chief Financial OfficerMediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III StudyMediWound Announces Collaboration with 3M on EscharEx® Phase III StudyMediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study DesignMediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal BurnsMediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled StudyMediWound to Report First Quarter 2024 Financial ResultsMediWound Reports First Quarter 2024 Financial Results and Provides Company UpdateMediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association CongressMediWound Reports Second Quarter 2024 Financial Results and Provides Company UpdateMediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. ArmyMediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in EuropeMediWound Announces Collaboration with MIMEDX on EscharEx® Phase III StudyMediWound Announces $25 Million Strategic Private Placement FinancingMediWound Reports Second Quarter 2023 Financial Results and Provides Company UpdateMediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial OfficerMediWound to Report Second Quarter 2024 Financial ResultsMediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator ProgramMediWound to Report Second Quarter 2023 Financial ResultsMediWound to Report First Quarter 2023 Financial ResultsMediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment ConferenceMediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell CarcinomaMediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal BurnsMediWound Deploys NexoBrid® for Emergency SupplyMediWound to Report Third Quarter 2023 Financial ResultsMediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial LoadsMediWound Announces Commercial Launch of NexoBrid® in JapanMediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company UpdateMediWound Announces an Additional $10 Million Award from BARDAMediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023MediWound to Participate in Two Upcoming Investor ConferencesMediWound Reports Third Quarter 2023 Financial Results and Provides Company UpdateMediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023MediWound to Report Fourth Quarter and Full Year 2023 Financial ResultsMediWound Reports First Quarter 2023 Financial Results and Provides a Company UpdateMediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric PatientsMediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg UlcersMediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
Company News
MediWound Ltd. (NASDAQ:MDWD) surges 19%; individual investors who own 46% shares profited along with institutions
Sep 29, 2023
Key Insights Significant control over MediWound by individual investors implies that the general public has more power...
Sep 29, 2023
MediWound Secures Additional U.S. Department of Defense - GlobeNewswireSep 26, 2023
R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution...
Sep 26, 2023MediWound Ltd. (MDWD) Q2 2023 Earnings Call TranscriptAug 16, 2023
MediWound Ltd. (NASDAQ:NASDAQ:MDWD) Q2 2023 Earnings Call Transcript August 16, 2023 8:30 AM ETCompany ParticipantsMonique Kosse - LifeSci Advisors, IROfer Gonen - Chief Executive...
Aug 16, 2023MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023Jun 14, 2023
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest. The conference will take place online from June 20 to June 22, 2023.
Jun 14, 2023MediWound Ltd. (MDWD) Q1 2023 Earnings Call TranscriptMay 30, 2023
MediWound Ltd. (NASDAQ:NASDAQ:MDWD) Q1 2023 Earnings Conference Call May 30, 2023 8:30 AM ETCompany ParticipantsMonique Kosse - LifeSci Advisors, IROfer Gonen - Chief Executive OfficerHani...
May 30, 2023Web Summary
Q1: What is the address of Mediwound's Global Headquarters?
A1: The address of Mediwound's Global Headquarters is 42 Hayarkon Street, Yavne 8122745 Israel.
Q2: What are the products developed by Mediwound?
A2: Mediwound develops NexoBrid, EscharEx, and MW005, which are topical biological drugs for the treatment of non-melanoma skin cancers.
Q3: In what industry is Mediwound operating?
A3: Mediwound operates in the pharmaceutical industry, specifically in the development of next-generation enzymatic therapeutics.
Q4: What services does Mediwound offer to its customers?
A4: Although not explicitly stated in the provided content, based on the company's description as a global leader in next-generation enzymatic therapeutics, it can be inferred that Mediwound offers therapeutic and treatment services for non-melanoma skin cancers.
Q5: What is the contact information of Mediwound USA?
A5: The contact information of Mediwound USA is 1007 North Organe Street, Wilmington DE 19801, with a phone number of +972 77 9714100 (which seems to be incorrect) and fax number also +972 77 9714100.
Q6: How can one get in touch with Mediwound for general inquiries?
A6: One can contact Mediwound for general inquiries by sending an email to info@mediwound.com or through their website's contact form.
Q7: What is the address of Mediwound's European Headquarters?
A7: The address of Mediwound's European Headquarters is Hans-Sachs-Str. 100, 65428 Rüsselsheim, Germany.
Q8: How can one get in touch with Mediwound for safety-related issues?
A8: One can contact Mediwound for safety-related issues by sending an email to safetymediwound@primevigilance.com.
A1: The address of Mediwound's Global Headquarters is 42 Hayarkon Street, Yavne 8122745 Israel.
Q2: What are the products developed by Mediwound?
A2: Mediwound develops NexoBrid, EscharEx, and MW005, which are topical biological drugs for the treatment of non-melanoma skin cancers.
Q3: In what industry is Mediwound operating?
A3: Mediwound operates in the pharmaceutical industry, specifically in the development of next-generation enzymatic therapeutics.
Q4: What services does Mediwound offer to its customers?
A4: Although not explicitly stated in the provided content, based on the company's description as a global leader in next-generation enzymatic therapeutics, it can be inferred that Mediwound offers therapeutic and treatment services for non-melanoma skin cancers.
Q5: What is the contact information of Mediwound USA?
A5: The contact information of Mediwound USA is 1007 North Organe Street, Wilmington DE 19801, with a phone number of +972 77 9714100 (which seems to be incorrect) and fax number also +972 77 9714100.
Q6: How can one get in touch with Mediwound for general inquiries?
A6: One can contact Mediwound for general inquiries by sending an email to info@mediwound.com or through their website's contact form.
Q7: What is the address of Mediwound's European Headquarters?
A7: The address of Mediwound's European Headquarters is Hans-Sachs-Str. 100, 65428 Rüsselsheim, Germany.
Q8: How can one get in touch with Mediwound for safety-related issues?
A8: One can contact Mediwound for safety-related issues by sending an email to safetymediwound@primevigilance.com.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
